Somatosensory Processing in Depression

This study is currently recruiting participants.

Verified by Ludwig-Maximilians - University of Munich, May 2008

Sponsors and Collaborators:	Ludwig-Maximilians - University of Munich H. Lundbeck A/S
Information provided by:	Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:	NCT00386893

Purpose

Aim of this study is to investigate neuronal differences (EEG/evoked potentials; functional MRI) between patients with major depression and healthy controls concerning brain activity after acute pain as well as changes of pain related brain activity during treatment with escitalopram.

Condition	Intervention	Phase
Depression	Procedure: simultaneous EEG/fMRI	Phase IV

MedlinePlus related topics: Depression

Drug Information available for: Escitalopram Benzetimide Citalopram Citalopram hydrobromide Dexetimide Escitalopram oxalate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study
Official Title:	Influence of Escitalopram on Somatosensory Processing in Patients With Major Depression

Further study details as provided by Ludwig-Maximilians - University of Munich:

Primary Outcome Measures:

changes in evoked potentials/functional MRI from baseline to week 4 [ Time Frame: two assessments, at baseline and week 4 ] [ Designated as safety issue: No ]

Estimated Enrollment:	30
Study Start Date:	October 2006
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Intervention Details:

fMRI/EEG recordings

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Psychiatric in or outpatients with acute depressive episode
Indication for pharmacological treatment

Exclusion Criteria:

Acute suicidal tendency
Neurological or severe somatic disorders
Women during pregnancy or lactation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00386893

Contacts

Contact: Oliver Pogarell, MD	+49 89 5160 ext 5540	oliver.pogarell@med.uni-muenchen.de
Contact: Susanne Karch, PhD	+49 89 5160 ext 5782	susanne.karch@med.uni-muenchen.de

Locations

Germany, Bavaria
Department of Psychiatry and Clin. Radiology, Ludwig-Maximilian-University	Recruiting
Munich, Bavaria, Germany, D - 80336
Contact: Oliver Pogarell, MD +49 89 5160 ext 5540 oliver.pogarell@med.uni-muenchen.de
Contact: Susanne Karch +49 89 5160 ext 5782 susanne.karch@med.uni-muenchen.de
Principal Investigator: Oliver Pogarell, MD

Sponsors and Collaborators

Ludwig-Maximilians - University of Munich

H. Lundbeck A/S

Investigators

Principal Investigator:

Ulrich Hegerl, MD

Department of Psychiatry, Ludwig-Maximilians-University

More Information

Responsible Party:	University of Munich ( S Karch, PhD )
Study ID Numbers:	ESC_03082005, 2005-003752-35
Study First Received:	October 10, 2006
Last Updated:	May 6, 2008
ClinicalTrials.gov Identifier:	NCT00386893
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Study placed in the following topic categories:

Depression
Mental Disorders
Mood Disorders
Depressive Disorder, Major

Dexetimide
Depressive Disorder
Citalopram
Behavioral Symptoms

ClinicalTrials.gov processed this record on January 16, 2009